aTyr Pharma, Inc.
ATYRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, aTyr Pharma, Inc. focuses on Biotechnology services and products. aTyr Pharma, Inc. aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and. The $47.2M market capitalization puts ATYR squarely in micro-cap range for its industry. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Market Cap
$47.2M
Beta
0.53
P/E (TTM)
—
P/E (Fwd)
-1.03
EPS (TTM)
$-0.63
EPS (Fwd)
$-0.47
ROE
-98.7%
ROA
-46.6%
Cash
$57.4M
Total Debt
$11.3M
Free CF
-$31.7M
52W Change
-90.5%
Annual Financials
Cash vs Debt
Where ATYR stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ATYR finished 28.99% below its 150-day moving average ($0.69) and 30.00% below its 200-day moving average ($0.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ATYR overbought or oversold?
At the September 3, 2026 close, ATYR's RSI(14) was 40.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $57.4M in cash and $11.3M in debt, ATYR maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$31.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -98.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $10.4M (2022) to $190K (2025), a 98% decline worth watching.
The relatively low beta of 0.53 suggests ATYR is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, ATYR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for aTyr Pharma, Inc. and its sector.